This only thing could reduce your pfizer antibodies, CDC study finds
New research highlighted a potential problem for a group of vaccinated people.
After more than oneStruggle A highly transmissible and mortal virus, being vaccinated against Covid is a moment of major relief. All threeU.S vaccines available-Pfizer, Moderna and Johnson & Johnson - have been proven very effective in protecting the general population against Covid. But the general population does not take into account the conditions or underlying factors that can affect how the vaccine works in some people. As soon as more research goes out, we are learning more and more about how some groups can produce reduced levels of antibodies after vaccination compared to others in the general population. Although researchers are not yet safe in the way the antibody response translates into virus protection, a new study has shown that your age could be one of these factors that reduce the antibodies you produce. Vaccine against Pfizer.
RELATED:The vaccine against Pfizer has been linked to this new side effect, the study says.
The study, which was conducted by disease control and prevention centers (CDC) and published on June 8 in theEmerging Infectious Diseases NewspaperAntibody Response among those who received the vaccine against Pfizer. The researchers compared the response of 71 seniors aged 81 and 123 health workers in Germany 34 years of age.
According to the study, the youngest health workers have always had higher levels of antibodies than the older group - even after totally vaccinated vaccination, two weeks after their second shot. At four weeks after the second dose, the two groups had their highest response rates, but the younger group had always much more pulling than the oldest. Researchers found that more than 99% of health workers in Germany showed IgG antibodies reactive at this stage, while only 91.4% of seniors showed the same thing.
The researchers noted that a "small fraction of the elderly did not demonstrate a reply for robust antibodies and T cells, even at four weeks after their second dose.
"A reminder vaccination, a dose of modified vaccine or various COVID-19 vaccines should be considered for seniors if other evidence demonstrates high rates of revolutionary infections despite 2 dose vaccination BNT162B2 (Pfizer)," concluded researchers.
RELATED:For more information up to date, sign up for our daily newsletter.
Pfizer has already worked on a booster vaccine. During an Axios event of May 20, Pfizer CEOAlbert Bourla says a booster shot can beNecessary at the beginning In September or October for some Americans, especially those who were in the first round of vaccinations, such as the elderly. CEO of ModernaStéphal Bantelechoed this feeling.
"The highest people (the elderly, health care workers) were vaccinated in December / January. So I would make [September] start with the highest risk," said Bondel.
However, older adults had not only reduced vaccine antibodies against Pfizer. They also had delayed antibody responses. In the first week after the first dose and just before the second, an antibody response was detected for nearly 87% of the youngest health workers. But an answer has not been detected for only 30% of the participants aged three weeks after the first dose, clearly indicating "a substantial delay and a reduced global antibody reaction in older participants," said researchers.
This also shines a light on a problem of general administration vaccination strategies the first dose of a series of two dose vaccines while reporting the second doses. "This practice can leave a relevant proportion of older people with relatively low immunity levels for an extended period, highlighting the need for non-pharmaceutical interventions, such as the use of masks and regular tests," noted researchers in their study.
RELATED:96% of people who get the vaccine against Pfizer have in common.
